Modern Healthcare - Collateral damage; Providers face negative fallout from the war on drugmakers.(health care providers)(Statistical Data Included)
The avalanche of civil whistleblower and class-action lawsuits, state and federal criminal investigations and antitrust inquiries involving the marketing and pricing practices of the prescription-drug industry is likely to ripple throughout the healthcare industry, leaving few provider sectors untouched, government officials and healthcare lawyers say.
Related Results
Boehringer, Abbott to co-promote Flomax - Brief Article
At work with… Stephen Neale
FDA Approves Three Hypertension Treatments.(Brief Article)(Statistical Data I…
Novartis settles dispute with FTC.(Brief Article)
FTC to Investigate Possible Pharma Collusion.(payoffs for delays of generic d…
Although most of the targets of the lawsuits are the pharmaceutical companies and their relationships with physicians and drug wholesalers, hospitals and healthcare systems are unlikely to completely dodge the latest antifraud …
Read the rest of this article with a Free Trial at HighBeam Research.
